Drug delivery system for the extended-release of larotrectinib based on a biocompatible Fe-based metal-organic framework: synthesis, characterization, in vitro release properties and antitumor evaluation
Larotrectinib (Lar) is an orally administered tropomyosin receptor kinase (Trk) inhibitor with broad-spectrum antitumor activity that is available in clinical dosage forms as capsules and oral solutions. Currently, corresponding research is focused on developing new extended-release formulation syst...
Main Authors: | Lu Gan, Peng Ji, Jin-xiang Zhang, Hao Chen, Yan-sheng Yao, Zhen-kun Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Bioengineering and Biotechnology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1197484/full |
Similar Items
-
Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases
by: Lucas Moratilla Lapeña, et al.
Published: (2022-01-01) -
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
by: Jesus Garcia-Foncillas, et al.
Published: (2022-03-01) -
Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review
by: Dandan Wang, et al.
Published: (2023-07-01) -
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
by: James C. H. Yang, et al.
Published: (2022-06-01) -
Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
by: Ruihe Lin, et al.
Published: (2023-10-01)